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Febrile nonhemolytic transfusion reactions (FNHTRs) 
are common complications resulting after transfusion of 
allogenic RBCs. Although they typically occur during the 
time of transfusion, these reactions may arise within 4–6 h 
after the transfusion. The frequency of febrile reactions in 
nonleukoreduced RBCs has been estimated to be 0.5–6.8% 
of all units transfused. [1,2] Patients with a history of FNHTRs 
are at a 15% risk of recurrence of this type of reaction.[3] 
Most FNHTRs are self-limited; they are characterized by 
fever (>1°C), chills and rigors. Nausea, vomiting, dyspnea, 
and hypotension may accompany these reactions, although 
they are not considered to be life threatening.[1]
White blood cells (WBCs or leukocytes) are considered to 
be an important cause of FNHTRs; the rate of WBC derived 
pro‑inflammatory cytokines increase with storage due to active 
synthesis of cytokines by these cells.[4] The interaction between 
the recipient’s cytoxic antibodies and human leukocyte 
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Abstract
Background: Febrile nonhemolytic transfusion reactions (FNHTRs) are relatively common 
complications associated with allogenic transfusion. White blood cells (WBCs or leukocytes) are 
considered to be an important cause of FNHTRs; the rate of WBC derived pro‑inflammatory 
cytokines increase with storage due to active synthesis of cytokines by these cells. The 
removal of the WBCs before storage will prevent the accumulation of cytokines during 
storage that leads to a reduction in the number of FNHTRs. Aim: We have conducted a 
retrospective analysis comparing the rate of FNHTRs in prestorage leukoreduced (PrSLR) 
and non leukoreduced RBCs transfusion. Subjects and Methods: A retrospective review of 
all the transfusion reactions (TRs) reported to the department over a period of 2 years from 
July 2012 to June 2014 was done. Patients were stratified by the date of reaction and by 
component received and then divided into two groups: (1) Patients who received allogeneic 
PrSLR RBCs and (2) nonleukoreduced RBCs. For the PrSLR RBC units, leukoreduction was 
performed by using buffy coat method of component preparation by quadruple bags and 
integral bags containing Sepacell® Pure RC filters (Fenwal™ France). Results: 37,232 RBCs 
units were transfused and out of which 14149 (38% i.e. is 14149/37232) were prestorage 
leukoreduced (PrSLR) and 23083 (62%) were non leukoreduced. A total of 142 (0.38%) TRs 
were reported during that time period, of which 62 (0.17%) were classified as FNHTRs. In 
the nonleukoreduced group 124 TRs were reported, of which 55 were classified as FNHTRs 
to RBCs and the overall rate of FNHTR to RBCs was 0.24%. In pre storage leukoreduced 
group, 18 TRs were reported, of which 7 were classified as FNHTRs to RBCs and the overall 
rate of FNHTR to RBCs was 0.05% (P ≤ 0.001). This represents a significant reduction in 
the rate of FNHTR after institution of prestorage leukoreduction. Conclusion: The rate of 
FNHTRs to allogenic RBC units after the implementation of prestorage leukoreduction has 
decreased significantly. Cytokines and chemokines accumulating during storage of cellular 
blood products are responsible for residual FNHTRs.
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antigen (HLA) or WBC‑specific antigens located on donor 
WBC’s, results in formation of antigen-antibody complexes 
leading to complement binding and release of endogenous 
pyrogens.[5] The removal of the WBCs before storage will both 
prevent the accumulation of cytokines during storage and will 
also remove the antigenic targets for preformed anti-WBC, 
leading to a reduction in the number of FNHTRs.[6] Despite 
the lack of change in cytokine levels during storage, prestorage 
leukoreduced (PrSLR) RBCs have been associated with lower 
rates of FNHTR compared to poststorage leukoreduced RBC 
units.[7,8] Poststorage WBC reduction has been shown to be 
equally effective in removing WBCs compared to prestorage 
WBC reduction and may even have added benefit of removing 
certain activated complement fragments, although it cannot 
abrogate the accumulation of WBC-derived cytokines during 
storage.[5]
Leukoreduced blood units were shown to minimize FNHTRs, 
HLA alloimmunization, platelet refractoriness and also prevent 
the transmission of leucotropic viruses such as cytomegalo 
virus (CMV), human T cell leukemia virus, and Ebstein 
bar virus.[9] Over the last 2 years, we have been gradually 
increasing our inventory of PrSLR RBCs, therefore we have 
conducted a retrospective analysis comparing the rate of 
FNHTRs in PrSLR and non leukoreduced RBCs transfusion 
in a tertiary care hospital.
Subjects and Methods
Study design
A retrospective review of all the transfusion reactions (TRs) 
reported to Department of Immunohematology and blood 
transfusion over a period of 2 years from July 2012 to 
June 2014 was done. Patients were stratified by the date 
of reaction and by component received and divided into 
two groups: (1) Patients who received allogeneic PrSLR 
RBCs and (2) allogeneic non leukoreduced RBCs. All 
RBC units, both leukoreduced and non leukoreduced 
were prepared in our component laboratory. For the 
PrSLR RBC units, leukoreduction was performed by 
using buffy coat method of component preparation by 
quadruple bags and integral bags containing Sepacell® 
Pure RC filter (Manufactured in France by Fenwal™ 
France and imported and marketed in India by Fenwal™ 
India, lot no 12G16 L02). Nonleukoreduced RBCs 
contain >109 WBCs. Leukoreduction by centrifugation and 
removal of buffy coat depleted RBCs give a log1 reduction 
(70–80%) of leukocytes in the unit (<5 × 108). Prestorage 
leukoreduction by Fenwal disposal: Sepacell® Pure RC 
filter from ASAHI produce a 2–4 log reduction (99–99.9%) 
of the WBCs (<5 × 106). Patients were not stratified on 
the basis of diagnosis, by inpatient or out-patient status 
at the time of the reaction. All data was categorized on a 
monthly basis. Reactions rates were calculated by dividing 
the number of reactions to each type of RBCs component 
by the total number of RBCs of that type transfused.
Evaluation of transfusion reactions
A standard TR investigation protocol was followed: All 
recognized TRs were reported to the blood bank on a standard 
reporting form. The clinical information included the patient’s 
pre and post transfusion vital signs and other symptoms noted 
during the reaction. Further consultation with the ward, staff, 
patient and chart reviews was performed to resolve ambiguities. 
The remaining blood component and a post transfusion blood 
sample from the patient was sent to the blood bank where 
a clerical check was performed in parallel with a DAT on 
the post transfusion sample. Visual inspection of the plasma 
component of the post transfusion sample was performed for 
evidence of hemolysis. At the discretion of the blood bank 
consultant, bacterial cultures of the remaining segments, bag, 
and patient may be performed. Once the investigation was 
complete, results were reviewed. Reactions were classified in 
accordance with the standards and recognized definitions by 
American association of blood banks.[10]
Statistics
Statistical analyses SPSS for Windows version 20.0 (SPSS iNC., 
Chicago, IL, USA). of the rates of FNHTRs to different types of 
RBC products were compared using the Chi‑square test.
Results
During the study period spanning 2 years, 37,232 RBCs units 
were transfused. Out of which 14149 (38% i.e. is 14149/37232) 
were pre storage leukoreduced and 23083 (62%) were non 
leukoreduced. A total of 142 (0.38%) TRs were reported 
during that time period, of which 62 (0.17%) were classified 
as FNHTRs. In the nonleukoreduced group 124 TRs were 
reported, of which 55 were classified as FNHTRs to RBCs and 
the overall rate of FNHTR to RBCs was 0.24%. In prestorage 
leukoreduced (PrSLR) group, 18 TRs were reported, of which 
7 were classified as FNHTRs to RBCs and the overall rate 
of FNHTR to RBCs was 0.05% (P ≤ 0.001) [Table 1]. This 
represents a significant reduction in the rate of FNHTR after 
institution of prestorage leukoreduction.
Discussion
Over the past 2 years, our department has gradually increased 
Table 1: Comparison of FNTHRs between PrSLR and 








Total RBCs transfusion 14,149 23,083
Total TR 18 124
FNHTRs 7 55
Rate FNHTRs 0.05 0.24
TRs (%) 0.13 0.54
PrSLR: Prestorage-leukoreduced, RBC: Red blood cell, FNHTRs: Febrile nonhemolytic 
transfusion reactions, TR: Transfusion reaction
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the inventory of leukoreduced RBCs with a final goal of 
achieving leukoreduced RBCs transfusion with time. We had 
a policy of selective leukoreduced tranfusion for patients of 
thalassemia and for those who had previously experienced a 
FNHTR but gradually oncology and multitransfused patients 
were also included. There is a controversy in literature 
about the acute efficacy of leukoreduced RBCs in reducing 
FNHTRs.[11,12] Therefore we performed this retrospective study 
to assess the rate of TRs in patients who received PrSLR and 
non leukoreduced RBCs. Our transfusion service has a very 
aggressive and comprehensive method for the surveillance of 
TRs; it has an excellent rapport with other clinical services 
and has residents for immediate follow-up and evaluation as 
soon as TRs are reported.
In the present study, the incidence of TRs was found to be 
0.38% in total, whereas in similar studies by University of 
Puerto Rico, Auckland Regional Blood centre and North 
India, who reported an incidence of 0.2%, 0.34%, 0.18% and 
0.05% respectively.[13-16] The overall rate of TRs with non 
leukoreduced RBCs was 0.54% which is comparable with 
those reported in the literature for nonleukoreduced RBCs.[1,3,17] 
Our rate of TR in PrSLR RBCs was 0.13% and in a similar 
study by King et al.[18] Yazer et al.[19] and Shanthala Devi,[17]
the rates of TRs were 0.40%, 0.69% and 0.26%.
We found a significant difference in the incidence of FNHTRs, 
that is, 0.05% versus 0.24% in PrSLR and nonleukoreduced 
RBCs. Several recent clinical trials have confirmed that 
prestorage leukocyte reduction is effective in reducing 
the rate of FNHTRs to red cells by approximately 50% 
with residual rates well below 1% [Table 2].[18-20] Serinolli 
et al.[21] reported a prospective trial in which the rate of 
FNHTR to nonleukoreduced RBCs (55/1521, 3.6%) was 
significantly higher than the rate of FNHTR to leukoreduced 
RBCs (13/1354, 1.0%).
The frequency of FNHTRs varies but with the use of 
leuco-reduced RBCs, the overall risk of FNHTRs has reduced 
to 0.24% in nonleukoreduced versus 0.05% in leukoreduced 
RBCs.[22] According to Sharma et al.[9] McNamara et al.[23] 
and Shapiro et al.[24] leukoreduction decreases the incidence 
of adverse effect of leucocytes in RBCs. In our study, the 
frequency of FNHTRs has been found to be consistently low, 
though increasing awareness and reporting about adverse 
reaction through hemovigilance system is balanced by the 
use of leukoreduced RBCs. There are a lot of variations in 
the frequency of FNHTRs among different studies throughout 
the world. This can be attributed to the variations in reporting 
system, frequent use of antipyretics and antihistaminics, 
and pretransfusion condition of the patient. This study has 
limitation because reaction rates were calculated from a 
retrospective review of passively reported reactions, under 
reporting of reaction could have lead to lower calculated 
rate of reactions and this can be improved by hemovigilance 
system. Leukoreduction has been particularly indicated in 
immunosuppressed patients who have an increased risk of 
transfusion‑acquired CMV infection. These high risk recipients 
include: Low birth weight infants, oncology patients, and 
allogenic bone marrow recipients. The transfusion of blood 
from CMV sero-negative and leukoreduced blood components 
to these patients has shown to decrease the risk to 1.3%[17] 
and 2.5%[25] respectively. Over the last two decades, major 
trails have clearly shown that the relative risk of HLA 
alloimmunization can be reduced considerably through the 
use of leukoreduced blood products.[26]
Conclusion
In conclusion our study demonstrated a significant decrease 
in the rate of FNHTRs to RBC units after the implementation 
of prestorage leukoreduction but cytokines and chemokines 
accumulating during storage of cellular blood products 
are responsible for residual FNHTR The questions of cost 
effectiveness and clinical relevance remain unanswered 
and will likely continue to be so until the other potential 
benefits of prestorage leukocyte reduction have been more 
fully elucidated. The reduction of FNHTRs is one of several 
arguments supporting the use of prestorage leukoreduction of 
RBCs and has a legitimate role to play in clinical transfusion 
practice. Patients who are multiple transfused, especially 
thalassemia major that have lifelong transfusion requirement, 
have the maximum benefit from such leukoreduced RBCs.
Limitation 
Clinical reporting was the only source of information about 
incidence of transfusion reactions, thus the accurate figure for 
transfusion reactions was difficult to obtain.
Implication of using retrospective data helped us to collect 
large sample size which can help us in calculating the incidence 
of reaction rates and helps in framing the policies to reduce 
the reaction rate.
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